Compare ADCT & CLPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADCT | CLPT |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 484.4M | 494.6M |
| IPO Year | 2019 | 2009 |
| Metric | ADCT | CLPT |
|---|---|---|
| Price | $4.18 | $9.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $7.50 | ★ $26.50 |
| AVG Volume (30 Days) | 784.0K | ★ 813.7K |
| Earning Date | 03-27-2026 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.90 | 22.22 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $70,837,000.00 | $31,390,000.00 |
| Revenue This Year | $14.96 | $18.93 |
| Revenue Next Year | $1.06 | $51.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 1.84 | ★ 31.04 |
| 52 Week Low | $1.05 | $8.63 |
| 52 Week High | $4.80 | $30.10 |
| Indicator | ADCT | CLPT |
|---|---|---|
| Relative Strength Index (RSI) | 53.63 | 29.55 |
| Support Level | $3.25 | N/A |
| Resistance Level | $4.71 | $11.69 |
| Average True Range (ATR) | 0.25 | 0.97 |
| MACD | -0.02 | -0.59 |
| Stochastic Oscillator | 36.90 | 8.15 |
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, ClearPoint Disposables, ClearPoint Software, and ClearPoint Therapeutic Solutions.